NICE rejects Cerdelga (eliglustat) as a cost effective treatment for type 1 Gaucher disease in its draft recommendation.- Sanofi
The National Institute of Health and Care Excellence (NICE) has provisionally not recommended Cerdelga (eliglustat) from Sanofi as a first-line oral treatment for adults with type 1 Gaucher disease in England.
NICE recognised that the therapy could provide “valuable quality-of-life benefits,” but at a substantial additional cost. Gaucher disease is usually treated through intravenous enzyme replacement therapy which is a time consuming and burdensome process. However, Cerdelga will cost £84,559 in the first year of treatment based on list prices and cost £571,487 by year 5. Sanofi offered a discount but it was not enough to persuade NICE.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins